Although the survival benefit of chemotherapy and anti-HER2 combination therapy has been established3,4; trends towards de-escalation are beginning to emerge, particularly as several novel anti-HER2 agents in advanced breast cancer are developing5–7. The gene discussed is ERBB2; the disease is breast cancer.